Protein kinase A inhibitor, H89, enhances survival and clonogenicity of dissociated human embryonic stem cells through Rho-associated coiled-coil containing protein kinase (ROCK) inhibition

被引:12
|
作者
Zhang, Liang [1 ,2 ]
Xu, Yanqing [1 ]
Xu, Jiandong [1 ]
Wei, Yuping [1 ]
Xu, Xia [1 ]
机构
[1] Chinese Acad Sci, Inst Proc Engn, State Key Lab Biochem Engn, Beijing 100190, Peoples R China
[2] Univ Chinese Acad Sci, Beijing 100049, Peoples R China
基金
中国国家自然科学基金;
关键词
human embryonic stem cells; H89; dissociation; cell survival; pluripotency; E-CADHERIN; DEPENDENT APOPTOSIS; DEFINED CONDITIONS; CULTURE-SYSTEM; SELF-RENEWAL; DIFFERENTIATION; EXPANSION; ACTIVATION; EXPRESSION; DERIVATION;
D O I
10.1093/humrep/dew011
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
STUDY QUESTION: Can cell survival of dissociated human embryonic stem cells (hESCs) be increased during culture? SUMMARY ANSWER: A protein kinase A (PKA) inhibitor, H89, can significantly enhance survival and clonogenicity of dissociated hESCs without affecting their pluripotency. WHAT IS KNOWN ALREADY: hESCs are vulnerable to massive cell death upon cellular detachment and dissociation. STUDY DESIGN, SIZE, DURATION: hESCs were dissociated into single cells and then cultured in feeder-dependent and -independent manners. H89 was added to the culture medium at different concentrations for 1 day. The statistical results were obtained from at least three independent experiments (n >= 4). The group without treatment was used as the negative control. PARTICIPANTS/MATERIALS, SETTING, METHODS: 4 mu M H89 was added in the culture medium to promote cell survival and colony formation of dissociated hESCs. MTT method and propidium iodide (PI) staining were used to determine cell proliferation, cell death and cell cycle, respectively. To count colony formation, alkaline phosphatase (AP) staining was carried out. Western blot was performed to determine protein expression. Except AP staining, immunofluorescence, RT-PCR and karyotype analysis were used to confirm the pluripotent state of H89 treated hESCs. MAIN RESULTS AND THE ROLE OF CHANGE: H89 inhibits the dissociation-induced phosphorylation of PKA and two substrates of Rho-associated coiled-coil containing protein kinase (ROCK), myosin light chain (MLC2) and myosin phosphatase target subunit 1 (MYPT1), significantly increases cell survival and colony formation, and strongly depresses dissociation-induced cell death and cell blebbing without affecting the pluripotency of hESCs and their differentiation in vitro. LIMITATIONS, REASONS FOR CAUTION: Appropriate H89 concentration should be used and 1 day of H89 treatment is sufficient for promoting survival and colony formation of dissociated hESCs. WIDER IMPLICATIONS OF THE FINDINGS: These results provide an alternative for human pluripotent stem cell (hPSC) culture, broaden the scope of participants in the cell death of single hES cells after dissociation and further enlighten clues to understand the mechanism of dissociation-induced cell death.
引用
收藏
页码:832 / 843
页数:12
相关论文
共 50 条
  • [1] Protein kinase A inhibitor, H89, significantly enhances survival rate of dissociated human embryonic stem cells following cryopreservation
    Zhang, Liang
    Xu, Yanqing
    Xu, Jiandong
    Wei, Yuping
    Xu, Xia
    CELL PROLIFERATION, 2016, 49 (05) : 589 - 598
  • [2] Inhibition of Rho-associated coiled-coil containing protein kinase enhances the activation of epidermal growth factor receptor in pancreatic cancer cells
    Nakashima, Masanori
    Adachi, Seiji
    Yasuda, Ichiro
    Yamauchi, Takahiro
    Kawaguchi, Junji
    Hanamatsu, Toshimasa
    Yoshioka, Takashi
    Okano, Yukio
    Hirose, Yoshinobu
    Kozawa, Osamu
    Moriwaki, Hisataka
    MOLECULAR CANCER, 2011, 10
  • [3] Inhibition of Rho-associated coiled-coil containing protein kinase enhances the activation of epidermal growth factor receptor in pancreatic cancer cells
    Masanori Nakashima
    Seiji Adachi
    Ichiro Yasuda
    Takahiro Yamauchi
    Junji Kawaguchi
    Toshimasa Hanamatsu
    Takashi Yoshioka
    Yukio Okano
    Yoshinobu Hirose
    Osamu Kozawa
    Hisataka Moriwaki
    Molecular Cancer, 10
  • [4] Targeting Rho-associated coiled-coil forming protein kinase (ROCK) in cardiovascular fibrosis and stiffening
    Yu, Brian
    Sladojevic, Nikola
    Blair, John E.
    Liao, James K.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2020, 24 (01) : 47 - 62
  • [5] Identification of the Rho-binding domain of p160(ROCK), a Rho-associated coiled-coil containing protein kinase
    Fujisawa, K
    Fujita, A
    Ishizaki, T
    Saito, Y
    Narumiya, S
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (38) : 23022 - 23028
  • [6] Transient rho-associated coiled-coil containing kinase (ROCK) inhibition on human retinal pigment epithelium results in persistent Rho/ROCK downregulation
    Kitahata, Shohei
    Ichikawa, Hinako
    Tanaka, Yuji
    Inoue, Tatsuya
    Kadonosono, Kazuaki
    BIOCHEMISTRY AND BIOPHYSICS REPORTS, 2020, 24
  • [7] Application of Rho-associated protein kinase (ROCK) inhibitor to human pluripotent stem cells
    Kurosawa, Hiroshi
    JOURNAL OF BIOSCIENCE AND BIOENGINEERING, 2012, 114 (06) : 577 - 581
  • [8] Regulation of Follicular Helper T (TFH) Cells By ROCK2 (Rho-associated coiled-coil containing protein kinase 2)
    Yi, Woelsung
    Gupta, Sanjay
    Weng, Chien-Huan
    Chinenov, Yurii
    Liao, James K.
    Pernis, Alessandra B.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [9] Involvement of Rho-Associated Coiled-Coil Containing Kinase (ROCK) in BCR-ABL1 Tyrosine Kinase Inhibitor Cardiovascular Toxicity
    Yu, Brian
    Osman, Afaf E.
    Sladojevic, Nikola
    Prabhu, Nicole
    Tai, Haw-Chih
    Chen, Daiqing
    Perla, Gerardo
    Park, Linus
    Larson, Richard A.
    Liao, James K.
    CIRCULATION, 2022, 146
  • [10] Involvement of Rho-Associated Coiled-Coil Containing Kinase (ROCK) in BCR-ABL1 Tyrosine Kinase Inhibitor Cardiovascular Toxicity
    Yu, Brian
    Osman, Afaf E. G.
    Sladojevic, Nikola
    Prabhu, Nicole
    Tai, Haw-Chih
    Chen, Daiqing
    Perla, Gerardo
    Park, Linus
    Larson, Richard A.
    Liao, James K.
    JACC: CARDIOONCOLOGY, 2022, 4 (03): : 371 - 383